Tanvex BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 12, 2023
Share
Tanvex BioPharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 5.11 million compared to TWD 8.33 million a year ago. Net loss was TWD 505.34 million compared to TWD 404.22 million a year ago. Basic loss per share from continuing operations was TWD 3.78 compared to TWD 3.44 a year ago. Diluted loss per share from continuing operations was TWD 3.78 compared to TWD 3.44 a year ago.
For the nine months, sales was TWD 52.32 million compared to TWD 14.5 million a year ago. Net loss was TWD 1,619.08 million compared to TWD 1,163.12 million a year ago. Basic loss per share from continuing operations was TWD 12.73 compared to TWD 9.89 a year ago. Diluted loss per share from continuing operations was TWD 12.73 compared to TWD 9.89 a year ago.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
TANVEX BIOPHARMA, INC. 
